This entry was posted on Monday, March 30th, 2009 at 4:55 am and is filed under Arthritis. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.
A BRIEFING ON THE ARTHRITIC PROCESS: CMO IS AN ADAPTOGENIC IMMUNOMODULATOR
From our work we have found that only CMO has corrective and restorative immunomodulatory properties for autoimmune diseases. Other so-called “immunomodulators” do not. They function primarily as immunosuppressants or immunostimulants. They are capable of only one principal action, either suppressing or stimulating immune function.
CMO, on the other hand, corrects autoimmune programs within the memory T-cells themselves rather than just temporarily suppressing or stimulating immune system activities. That is why a single CMO therapy program can correct memory T-cell faults without any need to continually apply the therapy or use any additional medication of any kind.
CMO is not an immunosuppressant, nor an immunostimulant. Nor is it a pharmaceutical. It is a naturally derived substance. Some practitioners have speculated that, in the case of arthritis for example, CMO merely acts upon pain receptors at the arthritic site. If that were so, CMO’s effects would not be so permanent. Furthermore, that theory cannot explain:
• how CMO lowers blood sedimentation rates in lupus patients,
• or how it reverses lung inflammation in emphysema,
• or how it lowers the need for insulin in diabetics,
• or how it reverses prostate inflammation,
• or how it relieves certain symptoms of multiple sclerosis,
• or how it corrects Crohn’s disease,
• or how it reverses fibromyalgia
• or how it lowers high blood pressure yet elevates low blood pressure,
• or how it benefits virtually any ailment with autoimmune components.
Obviously, CMO is a general remedial immunomodulator that acts upon the memory T-cells which control the autoimmune processes within our bodies. Those who speculate otherwise have misunderstood the physiological actions of CMO within the body.
It is also important to understand that CMO acts only upon memory T-cells and does not inhibit the activities of any of the several other types of T-cells or protective immune system agents that are responsible for combating invading microorganisms or intrusive substances.
Unlike the immunosuppressants commonly used to try to temporarily control the symptoms of autoimmune diseases, CMO does not leave the body vulnerable to attack by disease-causing agents. Nor does it inhibit the body’s resistance to tumor formation, as do the dangerous tumor necrosis factor (TNF) suppressants of some new arthritis drugs
*7\142\2*
Random Posts
Leave a Reply
You must be logged in to post a comment.